Related references
Note: Only part of the references are listed.Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
Robert P. Hasserjian et al.
BLOOD (2020)
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease
Alex Bataller et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
NPM1 Biology in Myeloid Neoplasia
Sanjay S. Patel et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Curtis A. Lachowiez et al.
BLOOD ADVANCES (2020)
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Chi Young Ok et al.
HAEMATOLOGICA (2019)
Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML
Erik Delsing Malmberg et al.
LEUKEMIA & LYMPHOMA (2019)
Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse
Richard D. Press et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications
Luise Hartmann et al.
GENES CHROMOSOMES & CANCER (2019)
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Adriano Venditti et al.
BLOOD (2019)
Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia
Federico Lussana et al.
CANCERS (2019)
Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing
Lauren L. Ritterhouse et al.
MOLECULAR DIAGNOSIS & THERAPY (2019)
Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation
Juliane Grimm et al.
BONE MARROW TRANSPLANTATION (2019)
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes
Prajwal C. Boddu et al.
CANCER (2019)
Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1
Yi Zhou et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Musa Yilmaz et al.
BLOOD CANCER JOURNAL (2019)
Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML
Yi Zhou et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia
Mithun Vinod Shah et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret et al.
HAEMATOLOGICA (2018)
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret et al.
HAEMATOLOGICA (2018)
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Anand Mayakonda et al.
GENOME RESEARCH (2018)
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
Fabio Forghieri et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
Nikhil Patkar et al.
Oncotarget (2018)
Clinical consequences of clonal hematopoiesis of indeterminate potential
David P. Steensma
BLOOD ADVANCES (2018)
Minimal residual disease in acute myelogenous leukemia
N. M. Cruz et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2017)
How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
Jie Xu et al.
CLINICS IN LABORATORY MEDICINE (2017)
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation
Bartlomiej M. Getta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia
Juan Ouyang et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)
Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists
Zhenya Tang et al.
MOLECULAR CYTOGENETICS (2016)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
Jeffery M. Klco et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia french association
Houria Debarri et al.
ONCOTARGET (2015)
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes
M. G. Della Porta et al.
LEUKEMIA (2015)
Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future
J. M. Jaso et al.
BONE MARROW TRANSPLANTATION (2014)
Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
Sanam Loghavi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse
Preetesh Jain et al.
LEUKEMIA & LYMPHOMA (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients
Mikako Warren et al.
MODERN PATHOLOGY (2012)
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group
T. M. Westers et al.
LEUKEMIA (2012)
Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia
Guilin Tang et al.
LEUKEMIA RESEARCH (2012)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
Nucleophosmin mutations in De novo acute myeloid leukemia:: The age-dependent incidences and the stability during disease
WC Chou et al.
CANCER RESEARCH (2006)
Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome
K Ogata et al.
BLOOD (2002)
Share Paper
